Analysts Weigh In On Auspex Pharmaceuticals Following Teva Acquisition

Israeli bio-tech company Teva Pharmaceutical announced that it will acquire neurology drug company Auspex Pharmaceuticals for an equity value of $3.5 billion in an effort to expand its treatments for the central nervous system.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.